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Introduction

Antibiotics Mode of Action

Antibiotic1 use in animal production has led to
improvedfeed use efficiency and increased growth rates.
In turn, these resulted in reduced food production costs
and reduced excrement of manure nutrients which may
cause pollution problems.

Antibiotics inhibit or kill susceptible bacteria in four
broad ways:

On the other hand, antibiotic use leads to antibiotic
resistance and a possible reduction in effectiveness of
treatment options for both animals and humans. This
publication addresses these issues.
Disease-causing microorganisms2, including
bacteria,are the most diverse and numerous organisms on earth. Diverse in their habitat, environmental
adaptation, and mechanisms of reproduction, they
have short generations with high multiplication rates.
Such characteristics help develop antibiotic resistance.
Resistance has developedto antibiotics used for human
treatment but very limited evidence is shown for
developmentof antibiotic resistance because of its use
in animal production.

1
Definitions for these terms in bold are given in the Definition of
Terms section at the end of the publication.
2
The term "microorganism" is used loosely in this publication to
refer to microscopic, often single-celled organisms causing major
animal and human diseases.

•
•
•
•

disruption of microbial cell wall synthesis;
inhibition of DNA replication;
inhibition of protein synthesis; and
inhibition of cell division, development, and
differentiation.

Resistance develops when a susceptible bacterium
develops an alternative path for its cell functions and
processes that are no longer inhibited by the antibiotic.
The most common source of antibiotic resistance
for microorganisms is genetic modification. The vast
majority of drug-resistant organisms emerge as a result
of single- or multiple-gene mutations. Resistance to an
antibiotic can develop when an organism acquires a foreign gene from another microorganism or picks a free or
“naked” gene source from the environment by a process
called transformation.
Resistance mechanisms are often specific to a particular antibiotic and bacterial species, and a specific
resistance mechanism may be limited to a specific
environment. However, the discovery of similar genes
and mechanisms across unrelated bacteria in some cases
suggeststhat such resistance genes have been transferred
between bacteria.

Antibiotic Use in Livestock Production
Antibiotics are used for therapeutic purposes
to prevent or control the development of disease in
humansand animals alike. Therapeutic antibiotic
use is often at a higher dose than “subtherapeutic”
purpose and is generallyadministered in water or by
injection. In livestock production, antibiotics are also
used at subtherapeutic level to promote growth and
increase feed efficiency. Subtherapeutic antibiotic use
in animals is administered as an additive to the feed or
through an implant. The use of antibiotics in feed is
a regulated activityunder the Code of Federal Regulations, Title 21, Part 558.
For use in the U.S., antibiotics for animal production
must be approved by the Food and Drug Administration
after rigorous evaluation for safety against major risk
factors with respect to the animal, the consumer, and the
environment. Antibiotics are assessed for:
• efficacy (the ability to achieve the claimed outcomes
by the manufacturer),
• target animal safety,
• environmental safety,
• human occupational safety, and
• human food safety.
The use of approved antibiotics is regulated and
instructionsmust be followed to avoid unintended consequences. The drug manufacturer, the regulatory agency,
the veterinarian, the producer, and the producer’s employees involved in administering the feed additive have collective responsibility for controlling unintended public health
impacts of antibiotic use in food-producinganimals.

Antibiotics Approved for Animal Production,
Mode of Action and Quantity Used
Antibiotics for Therapeutic Purpose
Antibiotics are used therapeutically to control an
infectiousdisease or treat a sick animal, preferably as
part of an integrated disease management approach
that incorporates other management components such
as minimizing external sources of infection on to the
farm and other biosecurity measures. Therapeutic antibiotic use is restrictively specific as to the type, quantity,
strength, frequency, length of use, route of administration, and withdrawal times (therapeutic regimen) as
dictated by the manufacturer’s label or by additional
label instructions from a veterinarian.
Antibiotics for Subtherapeutic Purpose
The use of subtherapeutic antibiotics is an impor
tant component of modern livestock production. Anti2
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biotics are added to feed in regulated small amounts for
maintaining health, promoting growth, and increasing
feed efficiency.
Subtherapeutic use must adhere to manufacturer’s
label instructions. These instructions help prevent
adverseeffects on the animals, avoid illegal levels of tissue residue, and allow appropriate withdrawal of the
antibiotic for the recommended time before the animal
product enters the food chain. The presence of an antibiotic residue in animal products above the regulatory
standard violates the Code of FederalRegulations, Title
21, and the animal product can be condemned in accordance with the federal Food, Drug & Cosmetic Act.
Regular intake of antibiotics as feed additives can
reduce disease risk and increase nutrient use efficiency
by reducing production of urea, methane, and ammonia
in the intestine. The improved efficiency gained through
antibiotic use decreases the amount of feed and land
necessary to raise the animals and decreases manure
productionper animal (Table 1).

Commonly Used Antibiotics
in the Production of Food Animals
A partial list of antibiotics used in the production of
swine, beef and cow-calf, and poultry is shown in Tables
2, 3, and 4. The list shows the name of the antibiotic, use
level, treatment objectives, and the required withdrawal
time. A complete list of FDA-approved animal drug
products can also be found in the FDA Green Book available at http://www.fda.gov/cvm/Green_Book/elecgbook.
html.
Antibiotic feed additive use is not common in milking dairies. The FDA will not accept drug residue in milk
or sale of milk from sick animals. Milk is checked by the
milk plant and by offices such as the office of dairy services at the state's department of agriculture. Tests can
detect a drug in milk from treated animals even when
this milk has been diluted in the tank by milk from many
cows.
Milk for human consumption must meet minimum
safety standards for somatic cell count (about 100,000),
bacteria counts, and have no antibiotic or chemical
residues. The FDA’s Pasteurized Milk Ordinance requires
Grade “A” milk delivered to dairy plants to be screened
for antibiotic residues prior to processing.
Screening is performed on milk samples obtained
from milk tank trucks arriving from farms at milk
assembly points. At the same time, producer samples
from individual farms on the load are tested, using the
same protocol when necessary.

Table 1. Physiological, nutritional, and metabolic effects ascribed to antibiotic feed additives in livestock
(+ shows an increase in response, - shows a decrease in response).
Physiological Effects
Growth and metabolism of
harmfulgut bacteria
Efficiency of nutrient absorption
by modifying the gut wall
Gut absorptive capacity
Fecal moisture
Mucosal cell turnover
Stress
Feed intake

Nutritional Effects

Metabolic Effects

-

Energy retention

+

Ammonia production

-

+

Gut energy loss

-

Toxic amine production

-

+
+

Nitrogen retention
Limiting amino acid supply
Vitamin absorption
Vitamin synthesis
Trace element absorption
Fatty acid absorption
Glucose absorption
Calcium absorption
Plasma nutrients

+
+
+
+
+
+
+
+

Alpha-toxin production
Fatty acid oxidation
Fecal fat excretion
Liver protein synthesis
Gut alkaline phosphatase
Gut urease
Methane
Toxic amine production

+
+
-

Table 2. FDA-approved commonly used antibiotics for therapeutic and subtherapeutic purposes in swine
production.
Drug
Apramycin
Arsanilic acid
Bacitracin methylene disalicyate
Bacitracin zinc
Bambermycins
Carbadox
Chlortetracycline
Lincomycin
Oxytetracycline
Penicillin
Roxarsone
Tiamulin hydrogen fumerate
Tilmicosin
Tylosin

Virginiamycin

Drug Use Level in Feed (g/ton) and
Treatment Objective
150 (Disease control)
45-90 (Feed efficiency and growth)
10-30 (Feed efficiency and growth)
250 (Disease control)
10-15 (Feed efficiency and growth)
20-40 (Feed efficiency)
2 (Feed efficiency and growth)
2-4 (Growth)
10-25 (Feed efficiency)
50 (Disease control)
10-50 (Feed efficiency and growth)
>50 (Disease control)
20 (Feed efficiency and growth)
40-200 (Disease control)
10-50 (Feed efficiency and growth)
22 (Disease control)
10-50 (Feed efficiency and growth)
23-34 (Feed efficiency and growth)
182 (Disease control)
10-11 (Feed efficiency and growth)
35-200 (Disease control)
181-363 (Disease control)
10-20 Finisher (Feed efficiency and growth)
20-40 Grower (Feed efficiency and growth)
20-110 Starter (Feed efficiency and growth)
10-100 (Disease control)
6-10 (Feed efficiency and growth)
>25 (Disease control)

Withdrawal Time (days)
28
5
None
None
None
None
None
None
42
42
None
None
None
None
5
5
None
5
5
None
2-7
7
None
None
None
None
None
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Table 3. FDA-approved commonly used antibiotics for therapeutic and subtherapeutic purpose in beef
and cow-calf1 production.
Drug

Drug Use Level in Feed (mg per head per day) and
Treatment Objective

Withdrawal Time (days)

Bacitracin zinc

35-70 (Feed efficiency and growth)

None

Bambermycins

1-5 (Feed efficiency and growth)
2-45 (Pasture, slaughter, feeder cattle growth)

None
None

Chlortetracycline

350 (Disease control)

Laidlomycin

5-10 (Feed efficiency and growth)

None

Lasalocid

10-30 (Feed efficiency and growth)

None

Monensin

5-30 (Feed efficiency, growth, and disease control)
25-400 (Intensive feeding and weight gain)

None
None

Oxytetracycline

75 (Feed efficiency and growth)
75 (Disease control)
0.1-5 mg per lb of body weight (Disease control)

None
None
0-5

Tylosin

8-10 (Disease control)

None

Virginiamycin

10-25 (Feed efficiency, growth, and disease control)

None

2

1
Foraging pasture constitutes the major proportion of a cow-calf ration as compared to purchased feeds. Hence antibiotics are formulated on a
per-head basis.

Table 4. FDA-approved commonly used antibiotics for therapeutic and subtherapeutic use in poultry
production
Drug

Drug Use Level in Feed (g/ton) and Treatment Objectives

Arsanilic acid

75-120 (Feed efficiency, growth, and pigmentation)

Avilamycin

5-10

None

Bacitracin

4-50 (Feed efficiency and growth)

None

Bambermycins

1-20 (Feed efficiency and growth)

None

Chlortetracycline

10-100 (Feed efficiency, growth, and disease control)

None

Lincomycin

2-4 (Feed efficiency and growth)

None

Oxytetracycline

5-50 (Feed efficiency, growth, and disease control)

Penicillin

2-50 (Feed efficiency and growth)

None

Roxarsone

23-46 (Feed efficiency, growth, and pigmentation)

None

Spiramycin (Banned in EU1)

5-20

None

Avoparcin (Banned in EU)

7.5-15

None

Tylosin (Banned in EU)

4-50 (Feed efficiency and growth)

None

Virginiamycin (Banned in EU)

5-20 (Feed efficiency and growth)

None

EU = European Union.

1

4
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Withdrawal Time (days)
5

0-3

A tank truck sample that tests positive will not be used
for humanconsumption. Moreover, the presence of antibiotics in milk interferes with the manufacture of several
dairy products such as delaying starter activity for cheese,
butter, and yogurt. Antibioticsalso decrease the acid and
flavor production associated with butter manufacturing,
in addition to reduced curdling of milk.

Human and Environmental Health Concern
Antibiotic Toxicity
To ensure consumer safety from antibiotic residues
in food animals, the drug sponsor conducts a number
of studies assessing the effect of the product on systemic toxicity, repeat dose toxicity, reproductive toxicity,
developmentaltoxicity, genotoxicity, carcinogenicity, and
human intestinal flora. The FDA reviews the methodology and results to set acceptable daily intake (ADI) and
maximum residue limits (MRL) and associated withdrawal time to allow the drug residue to deplete below
calculated MRL and ADI levels. Withdrawal time is
product-specific. A similar product could have different
withdrawal times depending on the difference in formulation of the product for a specific purpose.
Toxicology studies determine the dose at which no
adverse effect is observed. This dose is used to calculate:
1) the amount of drug residue that can be consumed by
an adult daily for a lifetime, without appreciable risk to
human health; and 2) the maximum residue limits of a
drug in a treated animal. Producers are required to follow label instructions and withdrawal times (Tables 2,
3, and 4) to keep drug residue in animal products from
reaching consumers.
According to a recent review by Lee and group,
the measured level of antibiotic concentrations in the
environment, including concentrations found in animal
manure and lagoon effluent, are lower than the level
believed to cause observable adverse effect on routinely
tested organisms. However, this general observation
should be understood in line with the limited research
information and limited field sample analysis potential. There are also some reported effects on nontarget organismsunder extreme conditions, which
include an observed negative effect of antibiotics on
microorganismsinvolved in normal soil processes such
as nitrification and organic matter decomposition.
Plant uptake of antibiotics from manure-applied
plots has been reported, although observed levels are
extremely low and not of concern to humans and animals feeding on these plants and plant products. Uptake
of sulfamethazine (an antibiotic) by corn, lettuce, and
potatoes has been documented with concentrations in
plant tissue ranging from 0.1 to 1.2 ppm dry weight. Sul-

famethazine concentration in plant tissue increased, with
concentration in the applied manure. However, the total
accumulation of sulfamethazine in the plant tissue after
45 days of active growth was less than 0.1 percent of the
total applied to soil in manure.
Antibiotic toxicity to humans is unlikely to be a
concern from antibiotics that may appear in animal
products or food crops receiving manure. Current FDA
approval processes have a proven history of protecting
human health from antibiotic residue in animal products. Currently, toxicity to humans via soil or water pathways appears very unlikely. However, additional research
may be needed to determine toxicity of antibiotics to
helpful microorganisms in manure and the soil.
Microbial Resistance to Antibiotics
The use of antibiotics may eliminate susceptible
microorganisms, leaving resistant ones behind. Such
resistant bacteria can cause an infection both in humans
and animals and may not respond to regular antibiotic
treatments. The emergence of such antibiotic-resistant
bacteria is a serious concern. People or animals infected
with resistant bacteria may be sick for a longer time than
with an infection caused by bacteria that is easily treatable with common antibiotics.
The FDA has published guidelines for an evidencebased approach to prevent antimicrobial resistance in
humans that may result from the use of antibiotics in
animals. This regulatory tool, known as Guidance #152,
is a checklist of points to consider when weighing the
potential human impact of a new animal drug. An electronic copy of Guidance #152 is available at http://www.
fda.gov/cdrh/oivd/guidance/152.pdf.
The National Antibiotics Resistance Monitoring
System (NARMS) monitors resistance to antimicrobial
drugs used in humans and food animals. Established in
1996, NARMS is a collaborative effort of the FDA, the
Centers for Disease Control and Prevention (CDC), and
the U.S. Department of Agriculture (USDA) facilitating a
nationwide system to track the change in susceptibility of
microorganisms to a wide range of antibiotics important
in human and animal medicine. Each year, samples are
taken and tested to determine changes over time in the
resistance of certain gut bacteria to selected antimicrobial drugs.
For example, approximately 30,000 samples of Salmonella isolates were tested from 1997 to 2003 and about
1 percent were found to be resistant. See the following
link for details: http://www.fda.gov/cvm/NARMSSB07White.htm. There is an increasing trend in resistance
for the isolates from human sources, but no clear trend
for isolates taken from food animals except for a slight
increase of Ceftiofur resistance in Salmonella among
© The Board of Regents of the University of Nebraska. All rights reserved.   5

cattle. The antibiotic drugs tested are selected based on
their importance in human and animal medicine (Table
5). Antibiotics of significant importance in human medicine may be banned for use in animal production or
restrictedto the therapeutic use under the prescription
or supervision of a veterinarian. For example, in July
2008, the FDA issued a prohibitive order limiting extralabel use of Cephalosporins in food-producing animals,
to limit the development of microbial resistance to this
class of drugs based on evidence gathered by NARMS.
There is genuine concern that using antibiotics in
large-scale animal production may contribute to more
instances of antibiotic resistance. However, the consensus
of reports from the FDA and other sources that looked
objectively into this issue found no conclusive evidence
of food-animal antibiotic use leading to resistance development in humans.
The FDA has acted and initiated the necessary
measureswhen there was a confirmed link in resistant
development to the use of a certain antibiotic in food
animal production and will likely continue to do so in
the future. However, constant assessment of this potential risk will need to continue in the future.

Economic Impact of Antibiotics
in Animal Production
Using antibiotics increases an animal’s daily weight
gain and reduces costs and feed inputs per unit of animal
product. Antibiotic use also improves feed efficiency by
reducing maintenance costs of the animal and providing protection at critical growth stages. Antibiotics also
reducemortality. The increased production efficiency
from using antibiotics is expected to:
• reduce the number of animals needed to produce a
given amount of animal product such as beef;
• reduce the level of inputs such as gasoline, fertilizer,
and insecticide used to produce feed; and

• reduce the amount of manure produced per unit of
animal production.
Therefore, gained efficiency in animal production
from using antibiotics should benefit the environment
and food supply. However, economic and environmental
benefits from antibiotic use in animal production must
be weighed against the risk for the development of resistance.

Management Options to Mitigate
Antibiotic Resistance
Minimizing antibiotic resistance risk, means using
antibiotics appropriately and judiciously. The American
Veterinary Medical Associations (AVMA) and the
FDA Center for Veterinary Medicine have developed
guidelines on the judicious use of antibiotics in order
to optimize resource use efficiency and to minimize
the development of antibioticresistance. See this
link for details: http://www.avma.org/issues/default.
asp#antimicrobials.
1. Prevent disease by providing integrated and sound
management systems:
• providing best-practice sanitation and hygiene;
• providing high-quality feed and protection from
the elements to reduce stress;
• implementing biosecurity measures;
• performing regular health exams;
• using vaccines; and
• controlling parasites.
2. Accurate and timely diagnosis of sick animals
ensuresproper and timely treatment methods.
3. If you must use antibiotics, work with a veterinarian to select the treatment option and to prepare a
writtentreatment protocol. Use proper dose, route,
treatment, and withdrawal time.
4. Treat the appropriate animals and the fewest number
of animals possible.

Table 5. Ranking of antibiotics for monitoring the emergence of resistance in the U.S.
Critically Important or High Concern

Highly Important or Medium Concern

Important or Low Concern

Broad spectrum Cephalosporins

Aminoglycosides

Narrow and expanded spectrum
Cephalosporins

Fluoroquinolones

Amoxicillin

Monobactams

Macrolides

Ampicillin

Quinolones

Lincosamides

Glycopeptides
Streptogramins
Tetracyclines

6
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5. Establish written protocols when using antibiotics.
6. Keep records of animal or group identification, drug
used, date treated, dosage used, route and location
for administration, who administered the product,
and any other useful information.
7. Work with a veterinarian to determine the most
effectivetherapy, and maintain a working relationship commonly referred to as “valid veterinarianclient-patient-relationship.” This means the
veterinarian knows the operation, the management
of the operation, the livestock, and is involved in any
diagnosis, treatment, and follow-up.
8. Use antibiotics and other medications as ordered.
It is the law.
9. Train people who treat livestock on your farm
operation.
10. Minimize environmental contamination.
Manure storage and treatment options may provide
additional means for reducing antibiotic risk in manure.
According to a study from Colorado, manure type and
treatment time determine the level of break-up for three
antibiotics (Chlortetracyline, Tylosin, and Monensin)
from manure before field application.
High-intensity management at storage (amending,
watering, and turning) reduced the half-life of the three
antibiotics to 4 to 15 days while watering or turning
alone reduced the half-life to 8 to 30 days. Thus, a 40day composting period would reduce concentrations by
approximately94 percent for the intensively managed
compost system (assumes 10-day half-life) and by 75
percent for the less intensive composting management
(20-day half-life). Additional reductions will occur during stockpiling or storage. More research is needed on
treatment or management options and their value for
reducing antibiotic concentration.

Impact of Eliminating Antibiotics:
Case Studies
The recent subtherapeutic antibiotic ban in
Europeprovides the opportunity to observe the consequences of antibiotic withdrawal. In Europe, the ban
of subtherapeutic use of antibiotics has been reported
by some to result in deterioration in animal health,
including increased diarrhea, weight loss, and mortality due to Escherichia coli and Lawsonia intracellularis
in early post-weaning pigs, and clostridial necrotic
enteritis in broilers. Furthermore, as a result of these
infections, there is an increase in usage of therapeutic
antibiotics, including that of tetracycline, aminoglycosides, trimethoprim/sulphonamide, macrolides, and

lincosamides, all of which are of direct importance in
human medicine. In Sweden, the ban of subtherapeutic antibioticscaused the age-to-30 kg body weight to
increaseby two days in pigs and increased the problems
of necrotic enteritis in broilers. The ban did not affect
egg production in layers, growth rate in turkeys, or productivity in specialized beef production. The Swedish
Animal Health Service concluded poultry, calves, and
pigs can be reared without continuous use of growth
promoters, if the benefits of other production practices
such as hygiene are maximized.
The ban on antibiotic feed additives in Europe
reducedthe incidence of resistance in indicator bacteria
in raw food products of animal origin. While the carriage
of certain resistant pathogens among healthy individuals has diminished, there has been no apparent positive
impact on the level of antibiotic resistance in human
patients or in hospitals. Moreover, the incidence of
food-borne disease continued to rise in Europe for some
bacteria such as Salmonella, highlighting the complexity
of any potential relationship between antibiotic use in
livestock and antibiotic-resistant disease in humans.

Conclusions
Using antibiotics to increase feed efficiency or for
therapeutic purposes will contribute to the emergence
of resistant microorganisms. At this time, there’s limited
evidence that this resistance impacts human health.
However, this risk cannot be ignored. Current regulation
of antibiotic use for animal health, field monitoring of
resistance, and research will be essential to understand
and minimize these risks.
Important points to take away from this publication
are the following:
• All antibiotics should be used judiciously.
• Microorganisms are constantly mutating or
exchangingDNA with each other and with the
environment,which could result in the development of resistance for existing antibiotics. Resistance development is a natural process as much as
it is induced by the presence of antibiotics in the
environment.
• Regulations are in place to reserve some broad
spectrum antibiotics of critical importance for
humantreatment.
• The use of antibiotics increases selection pressure for microbial resistance. However, the issue
is complex and a link of increased microbial resistance in human illnesses to a single factor such as
the use of antibiotics in livestock production has
not been verified.
© The Board of Regents of the University of Nebraska. All rights reserved.   7

• Strict regulations are in place to limit the transfer
of antibiotic residue to consumers through animal
products of treated animals, as well as to prevent
antibiotic toxicity concerns from food products of
treated animals.
• Antibiotics are detected in manures, soils, and
water but at concentrations below levels that cause
toxic effects on non-target organisms including humans. However, these concentrations may
increasethe development of antibiotic resistance.

• Reduced antibiotic resistance development in animal agriculture currently focuses on use of bestmanagement practices in the use of antibiotics as
developed by the AMVA and FDA.
• Recent efforts to ban subtherapeutic use of anti
biotics in animal agriculture in Europe have
not clearly reduced antibiotic-resistant disease
in humans to date, and may result in decreased
productivityand other negative environmental
consequences.

Definition of Terms
Antimicrobial: a broad class of natural, synthetic, or semi-synthetic products that kill or inhibit the growth
of bacteria or other microorganisms. Antimicrobials include antibiotics and these terms are often used
synonymously.
Antibiotics: a substance that is naturally produced by a microorganism that can kill or inhibit the growth of other
microorganisms at a very low concentration.
Bacteria: single-cell organisms that may cause disease in animals and humans and are treated by antibiotics. Other
disease-causing organisms, such as viruses, are not treated by antibiotics.
Extra-label use of antibiotic: the actual or intended use of a drug in a manner not in accordance with the
approvedlabeling. The provision for such use establishes certain conditions under which veterinarians are
permitted to use approved animal or human drugs in an extra-label manner in animals. (This includeswhat is
commonly known as subtherapeuticuse.)
Microorganisms (for the purposes of this guide): single-celled organisms causing major animal and human
diseases.
Necrotic enteritis is a disease caused by Clostridium perfringens. Signs include droopiness, lack of appetite, diarrhea,
ruffled feathers, and mortality in the flock, sometimes occurring quite suddenly. The disease is common at a
young age and rarely occurs after 30 days of age.
Subtherapeutic use: the use of antibiotics below a diseasetreatment or control threshold for the purpose of
improvedfeed efficiency or weight gain. “Subtherapeutic” is a term mainly adopted by organizations and
individuals questioning the use of antibiotics for purposes other than the treatment of diseased animals or to
prevent the development of a disease.
Therapeutic use: the use of antibiotics for the treatment of infectious diseases. Therapeutic antibiotics are given at
a higher dose than subtherapeutics and are generally administered in water or by injection.
Withdrawal (withholding) time: The time from when an animal was last given a drug to when it is considered
safe for human consumption (marketing of the animal product).

8
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